Shibuya chooses ADVA to deliver encrypted services to Nordic banks
16.2.2023 11:00:00 EET | Business Wire | Press release
ADVA (FSE: ADV) today announced that Shibuya is deploying its open optical technology to deliver secure managed services to leading banks across the Nordics and Baltics. The new network features robust optical encryption cards from Adva Network Security for critical data protection. Shibuya, a leading Swedish IT service provider and ADVA’s long-term Select partner, is using the solution to offer highly available connectivity with end-to-end data protection.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230215005611/en/
ADVA’s technology is helping banks securely transport mission-critical data throughout the Nordic and Baltic regions. (Photo: Business Wire)
“For our financial customers, security couldn’t be more crucial. That’s why we’re ensuring that our managed services protect data in motion with the most robust defense available. At Shibuya, we specialize in delivering secure and sustainable IT environments, and ADVA’s solutions are a perfect fit,” said Jessica Liljefors, business area manager at ShibuyaCare, Shibuya. “Adva Network Security‘s encryption technology and the unique experience of its team help us deliver the strongest possible protection and offer complete peace of mind to our banking clients and their customers. Combined with our extensive cybersecurity measures, local data centers near the customers and 24/7 IT support, we can provide the high-end services demanded by the financial sector.”
The new solution safeguards mission-critical financial traffic using ConnectGuard™ Optical encryption technology provided by Adva Network Security. The technology protects data in-flight to the strictest regulatory requirements with minimal impact on throughput. Part of the new infrastructure is built on the ADVA FSP 3000 TeraFlex™ platform, which uses ultra-flexible modulation with fractional QAM. This supports 600Gbit/s streams while ensuring the lowest possible cost per bit. ADVA’s technology also supports the latest generations of low-latency Fibre Channel, empowering financial network operators to keep up with the requirements of new server and storage technologies – a key consideration for Shibuya and some of its enterprise customers.
“The reputation of today’s financial institutions is built on trust and confidence. By enabling banking customers to harness our TeraFlex™ terminal and enterprise cards, Shibuya is ensuring that Nordic financial enterprises can protect the integrity of highly sensitive data wherever it happens to be in the network. What’s more, our technology delivers the highest levels of performance while also reducing cost per bit,” commented Hartmut Müller-Leitloff, SVP of sales EMEA at ADVA. “And for major banks, being able to utilize the best available storage area network protocols is also key for meeting new business continuity needs and staying operational in the face of any disruption.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com.
About Shibuya
Shibuya creates secure and sustainable IT environments for a digital Sweden. The company is one of the country’s premier operators in business-critical IT and delivers services in, among other things, data center infrastructure and IT operation, hybrid cloud solutions, cyber security, 24/7 IT service and support, communication, application operations and third-party services. Shibuya has strategic partnerships with leading manufacturers and reference solutions with several of the Nordics’ most demanding IT operations in both the private and public sectors. The company is certified according to ISO 14001, 9001 and 27001 standards and is part of the Pulsen Group. www.shibuya.se
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230215005611/en/
Contact information
For press:
Gareth Spence
t +44 1904 699 358
public-relations@adva.com
For investors:
Stephan Rettenberger
t +49 89 890 665 854
investor-relations@adva.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom